Krystal Biotech, Inc. KRYS Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s change in other liabilities?
- Krystal Biotech, Inc. (KRYS) reported change in other liabilities of $1.44M in Q1 2026.
- How has Krystal Biotech, Inc.'s change in other liabilities changed year-over-year?
- Krystal Biotech, Inc.'s change in other liabilities increased by 168.7% year-over-year, from $534K to $1.44M.
- What does change in other liabilities mean?
- The net change in miscellaneous short-term debts or obligations.
- How do you interpret change in other liabilities?
- An increase provides a source of cash, while a decrease represents a cash outflow as these obligations are settled.
- How does change in other liabilities compare across companies?
- Common across all industries, though the composition of 'other' varies significantly by company.